Literature DB >> 26604264

Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.

Hervé Poulet1, Jean-Christophe Thibault2, Alonso Masias3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26604264      PMCID： PMC4658589          DOI： 10.1128/CVI.00497-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


× No keyword cloud information.
  14 in total

Review 1.  Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies.

Authors:  D Franchimont
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

2.  Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays.

Authors:  Regina Hofmann-Lehmann; Ravi Tandon; Felicitas S Boretti; Marina L Meli; Barbara Willi; Valentino Cattori; Maria A Gomes-Keller; Pete Ossent; Matthew C Golder; J Norman Flynn; Hans Lutz
Journal:  Vaccine       Date:  2005-09-19       Impact factor: 3.641

Review 3.  Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression.

Authors:  Mark Löwenberg; Auke P Verhaar; Gijs R van den Brink; Daniel W Hommes
Journal:  Trends Mol Med       Date:  2007-02-09       Impact factor: 11.951

4.  Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats.

Authors:  Regina Hofmann-Lehmann; Jon B Huder; Sabine Gruber; Felicitas Boretti; Brigitte Sigrist; Hans Lutz
Journal:  J Gen Virol       Date:  2001-07       Impact factor: 3.891

5.  Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.

Authors:  Deborah A Grosenbaugh; Tim Leard; M Camila Pardo
Journal:  J Am Vet Med Assoc       Date:  2006-03-01       Impact factor: 1.936

6.  Re-examination of feline leukemia virus: host relationships using real-time PCR.

Authors:  Andrea N Torres; Candace K Mathiason; Edward A Hoover
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

7.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

8.  Efficacy of a canarypox virus-vectored vaccine against feline leukaemia.

Authors:  H Poulet; S Brunet; C Boularand; A L Guiot; V Leroy; J Tartaglia; J Minke; J C Audonnet; P Desmettre
Journal:  Vet Rec       Date:  2003-08-02       Impact factor: 2.695

9.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

10.  Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL.

Authors:  J Tartaglia; O Jarrett; J C Neil; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.